ALTME:EPA
TME Pharma NV
€0.11
arrow_downward
-0.36%(-0.00040) 1D
Okt 20, 10:48:31 AM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa ALTME...
Buksan
€0.11
Mataas
€0.11
Mababa
€0.10
Mkt. cap
10.58M
Avg. na dami
1.85M
Dami
94.73K
Mataas nang 52-wk
€0.17
Mababa nang 52-wk
€0.05
EPS
-€0.03
Bilang ng mga empleyado
0
Buksan
€0.11
Mataas
€0.11
Mababa
€0.10
Mkt. cap
10.58M
Avg. na dami
1.85M
Dami
94.73K
Mataas nang 52-wk
€0.17
Mababa nang 52-wk
€0.05
EPS
-€0.03
Bilang ng mga empleyado
0
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
CNBC
·
13 oras ang nakalipas
The turnaround of this beaten-up Dow stock looks for real, says Katie Stockton
CNBC
·
8 oras ang nakalipas
CNBC Daily Open: Tech investors buy the dip — but debt remains a concern
24/7 Wall St.
·
6 araw ang nakalipas
These 3 International Dividend ETFs Outyield SCHD and Are Beating the S&P 500 Over the Past Year
MarketWatch
·
4 araw ang nakalipas
There’s a ‘monstrous bull market’ developing under the surface of the S&P 500. This hedge-fund manager tells you where it’s at.
Profile
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Tungkol sa TME Pharma NV